We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+18.47%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.6B
AUM Growth
+$886M
Cap. Flow
+$257M
Cap. Flow %
4.58%
Top 10 Hldgs %
40.08%
Holding
154
New
29
Increased
38
Reduced
31
Closed
27

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$93.3M
2
BMY icon
Bristol-Myers Squibb
BMY
+$82.6M
3
SHPG
Shire pic
SHPG
+$76.4M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$50.3M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$49.2M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$149M
2
INCY icon
Incyte
INCY
+$33.4M
3
MAKO
MAKO SURGICAL CORP COM
MAKO
+$26.7M
4
PFE icon
Pfizer
PFE
+$25.6M
5
AGN
Allergan plc
AGN
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 85.38%
2 Miscellaneous 12.69%
3 Financials 1.77%
4 Technology 0.15%
5 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$180B
$300M 5.36%
4,777,800
-44,000
-0.9% -$2.63M
AMGN icon
2
Amgen
AMGN
$204B
$294M 5.25%
2,629,600
+10,200
+0.4% +$1.11M
MRK icon
3
Merck
MRK
$354B
$289M 5.16%
6,367,648
+2,044,229
+47% +$93.3M
BIIB icon
4
Biogen
BIIB
$31.9B
$247M 4.41%
1,026,400
+600
+0.1% +$134K
BMY icon
5
Bristol-Myers Squibb
BMY
$130B
$241M 4.3%
5,204,000
+1,882,000
+57% +$82.6M
CELG
6
DELISTED
Celgene Corp
CELG
$201M 3.59%
2,614,000
+141,200
+6% +$9.9M
VTRS icon
7
Viatris
VTRS
$18.8B
$193M 3.44%
5,049,000
+62,000
+1% +$2.18M
INCY icon
8
Incyte
INCY
$24.4B
$171M 3.05%
4,473,000
-1,133,000
-20% -$33.4M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$80.1B
$161M 2.86%
513,100
+162,000
+46% +$42.6M
ICPT
10
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$149M 2.65%
2,151,607
+973
+0% +$48K
TMO icon
11
Thermo Fisher Scientific
TMO
$233B
$142M 2.54%
1,546,000
-240,000
-13% -$21.7M
MDVN
12
DELISTED
MEDIVATION, INC.
MDVN
$137M 2.44%
4,569,000
+1,624,800
+55% +$46.4M
HCA icon
13
HCA Healthcare
HCA
$91.9B
$131M 2.33%
3,053,000
-313,300
-9% -$12.2M
ILMN icon
14
Illumina
ILMN
$32.5B
$129M 2.3%
1,638,426
-59,624
-4% -$4.56M
PFE icon
15
Pfizer
PFE
$157B
$115M 2.06%
4,226,962
-941,116
-18% -$25.6M
A icon
16
Agilent Technologies
A
$42.1B
$115M 2.05%
3,139,908
+548,016
+21% +$18.5M
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$12.6B
$114M 2.04%
1,581,700
+240,500
+18% +$16M
ESRX
18
DELISTED
Express Scripts Holding Company
ESRX
$110M 1.97%
1,783,000
-124,170
-7% -$8.03M
PODD icon
19
Insulet
PODD
$9.59B
$103M 1.84%
2,852,500
-196,000
-6% -$6.58M
ELV icon
20
Elevance Health
ELV
$90.4B
$101M 1.8%
1,206,000
+19,000
+2% +$1.63M
AET
21
DELISTED
Aetna Inc
AET
$99.4M 1.77%
1,553,000
+34,000
+2% +$2.18M
UNH icon
22
UnitedHealth
UNH
$339B
$95.2M 1.7%
1,329,000
+121,000
+10% +$8.66M
SHPG
23
DELISTED
Shire pic
SHPG
$82.8M 1.48%
+690,900
New +$76.4M
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$80M 1.43%
4,592,600
+71,800
+2% +$1.37M
ABBV icon
25
AbbVie
ABBV
$463B
$77.9M 1.39%
1,742,000
-35,000
-2% -$1.55M
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2013 Portfolio in Review

As of Q3 2013, OrbiMed held 154 positions worth $5.6B, up 19% from $4.72B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed deployed $257M of net new capital in Q3 2013, opening 29 new positions and adding to 38 existing holdings. Its largest new stake was Shire pic: 690,900 shares worth $82.8M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Incyte, an estimated $33.4M trimmed.

  • OrbiMed's largest Q3 2013 buy was Shire pic: 690,900 shares worth $82.8M.
  • OrbiMed added most to Merck in Q3 2013, an estimated $93.3M increase.
  • OrbiMed's biggest Q3 2013 reduction was Incyte, cutting an estimated $33.4M.
  • OrbiMed fully exited ONYX PHARMACEUTICALS INC in Q3 2013, selling an estimated $149M.
  • OrbiMed's ten largest holdings make up 40% of its $5.6B portfolio in Q3 2013.
  • OrbiMed opened 29 new positions and closed 27 in Q3 2013.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $5.6B.

Based on OrbiMed's 13F filing for Q3 2013, filed 14 Nov 2013.